NeoGenomics is an oncology diagnostics company trading at a compelling 18% potential upside relative to analyst price targets, but weak quality metrics and an unfavorable risk/reward profile at current levels make the investment speculative until margin improvement materializes.
Thesis pillars
- Oncology Diagnostics Revenue Growth→Stable
- Earnings Beat Momentum→Stable
- Valuation Growth Combination→Stable
- +1 more pillar — see the Why tab for full reasoning
NeoGenomics, Inc. (NEO) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $15.13: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality.
NeoGenomics provides oncology diagnostic testing and consultative services through a network of CAP-accredited, CLIA-certified laboratories in Florida, California, North Carolina, New Jersey, Texas and the United Kingdom, offering cytogenetics, FISH, flow cytometry,... Read more
Sell if holding. Engine safety override at $15.13: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.6/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 23d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-07-07Recent Developments — NeoGenomics, Inc.
Latest news
- NEWS NeoGenomics Prices Offering Of $275M Of 0.75% Convertible Senior Notes Due 2032 — benzinga Jun 17, 2026 neutral
- NEWS NeoGenomics Commences A Private Offering Of $275M Aggregate Principal Amount Of Convertible Senior Notes Due 2032 — benzinga Jun 15, 2026 neutral
- NEWS NeoGenomics To Showcase Eight Scientific Abstracts, Highlighting Advances In MRD, Precision Oncology, And Real-World Evi — benzinga May 26, 2026 positive
- NEWS Earnings Scheduled For May 12, 2026 — benzinga May 12, 2026 neutral
- NEWS Benchmark Upgrades NeoGenomics to Buy, Announces $11 Price Target — benzinga Apr 29, 2026 positive
Generated 2026-07-07T11:41:56Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-06-25Item 5.02LOWOn June 23, 2026 NeoGenomics' Board expanded to ten directors and appointed Carolyn S. Starrett to fill the new seat, effective immediately. Routine board appointment; she will serve until the 2027 annual meeting.SEC filing →
- 2026-05-22Item 5.02LOWAt NeoGenomics' May 21, 2026 annual meeting, stockholders approved a second amendment to the 2023 Equity Incentive Plan, adding 5,000,000 shares available for issuance. Routine equity-plan increase.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Unprofitable operations — net margin -13.3%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.13: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $14.10. Score 5.6/10, moderate confidence.
Take-profit target: $15.26 (+0.7% upside). Prior stop was $14.10. Stop-loss: $14.10.
Target reached (-13.3% upside); Quality below floor (3.5 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.6), Material insider selling (4 sells, 0.09% of cap).
NeoGenomics, Inc. trades at a P/E of N/A (forward 41.6). TrendMatrix value score: 6.5/10. Verdict: Sell.
16 analysts cover NEO with a consensus score of 3.9/5. Average price target: $15.
What does NeoGenomics, Inc. do?NeoGenomics provides oncology diagnostic testing and consultative services through a network of CAP-accredited,...
NeoGenomics provides oncology diagnostic testing and consultative services through a network of CAP-accredited, CLIA-certified laboratories in Florida, California, North Carolina, New Jersey, Texas and the United Kingdom, offering cytogenetics, FISH, flow cytometry, molecular/NGS testing and molecular residual disease (MRD) monitoring. The company serves community pathology practices, hospital labs, academic centers and pharmaceutical companies, competing against Quest Diagnostics, LabCorp, Guardant Health, Natera and Myriad Genetics. No single client accounted for more than 10% of NeoGenomics